FNY Investment Advisers’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Buy
50,150
+33,960
+210% +$888K 0.43% 57
2026
Q1
$454K Buy
16,190
+8,860
+121% +$236K 0.2% 110
2025
Q4
$182K Sell
7,330
-15,592
-68% -$393K 0.05% 247
2025
Q3
$584K Sell
22,922
-4,402
-16% -$109K 0.19% 145
2025
Q2
$662K Buy
27,324
+10,414
+62% +$243K 0.28% 101
2025
Q1
$428K Buy
16,910
+3,446
+26% +$90.2K 0.26% 86
2024
Q4
$357K Buy
13,464
+7,075
+111% +$192K 0.18% 112
2024
Q3
$184K Sell
6,389
-265
-4% -$7.73K 0.09% 173
2024
Q2
$186K Buy
6,654
+4,654
+233% +$128K 0.12% 123
2024
Q1
$55 Buy
2,000
+1,112
+125% +$30.9K 0.03% 249
2023
Q4
$25K Buy
+888
New +$26.8K 0.03% 248
2023
Q3
Sell
-29,500
Closed -$1.04M 715
2023
Q2
$1.08M Buy
+29,500
New +$1.15M 1.37% 17
2022
Q2
Sell
-3,776
Closed -$192K 849
2022
Q1
$195K Buy
+3,776
New +$196K 0.18% 106
2021
Q3
Sell
-200
Closed -$7K 878
2021
Q2
$7K Buy
+200
New +$7.78K ﹤0.01% 605
2021
Q1
Sell
-13,975
Closed -$514K 962
2020
Q4
$514K Buy
+13,975
New +$513K 0.14% 133
2020
Q1
Sell
-211
Closed -$7K 728
2019
Q4
$7K Buy
+211
New +$7.52K ﹤0.01% 658

Other funds holding PFE

FNY Investment Advisers's PFE Position: Q2 2026 in Review

FNY Investment Advisers increased its Pfizer (PFE) stake by 210% in Q2 2026, buying an estimated $888K and bringing the position to 50,150 shares worth $1.21M. The position accounts for 0.43% of the portfolio, ranked #57.

FNY Investment Advisers first reported a position in PFE in Q4 2019 and has held it in 16 quarters since. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • FNY Investment Advisers held 50,150 shares of Pfizer worth $1.21M as of Q2 2026.
  • FNY Investment Advisers bought 33,960 Pfizer shares in Q2 2026, an estimated $888K.
  • Pfizer made up 0.43% of FNY Investment Advisers's portfolio in Q2 2026, its #57 holding.
  • FNY Investment Advisers first reported a position in Pfizer in Q4 2019 and has held it in 16 quarters since.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.